



Elevated TyG Index Predicts Progression of Coronary Artery Calcification

Kahui Park,¹ Chul Woo Ahn,^{1,2}
Sang Bae Lee,¹ Shinae Kang,^{1,2}
Ji Sun Nam,^{1,2} Byoung Kwon Lee,³
Jung Hye Kim,¹ and Jong Suk Park^{1,2}

Diabetes Care 2019;42:1569–1573 | <https://doi.org/10.2337/dc18-1920>

OBJECTIVE

To investigate the triglyceride-glucose (TyG) index association with coronary artery calcification (CAC) progression in adult Koreans.

RESEARCH DESIGN AND METHODS

Various cardiovascular risk factors and anthropometric profiles were assessed in 1,175 subjects who previously had a CAC evaluation at least twice by multi-detector computed tomography in a health care center. The TyG index was determined using $\ln(\text{fasting triglycerides [mg/dL]} \times \text{fasting glucose [mg/dL]}/2)$. The CAC progression was defined as either incident CAC in a CAC-free population at baseline or an increase of ≥ 2.5 units between the square roots of the baseline and follow-up coronary artery calcium scores (CACs) of subjects with detectable CAC at baseline.

RESULTS

CAC progression was seen in 312 subjects (27%) during 4.2 years follow-up. On the basis of the TyG index, subjects were stratified into three groups. Follow-up CACs and incidence of CAC progression were markedly elevated with rising TyG index tertile. Logistic regression analysis adjusted for various risk factors revealed an odds ratio for CAC progression of 1.82 (95% CI 1.20–2.77; $P \leq 0.01$) when the highest and lowest TyG index tertiles were compared.

CONCLUSIONS

The TyG index is an independent predictor of CAC progression.

Understanding the progression of cardiovascular disease (CVD) is important because the disease can lead to severe morbidity and mortality. An important risk factor for CVD is coronary artery calcification (CAC), and cardiovascular risk is commonly assessed by coronary artery calcium score (CACS), as determined by computed tomography (CT) (1–4).

Insulin resistance (IR) is one of the major factors that leads to CVD, and several earlier studies have shown a relationship between IR and CAC (5,6). A reliable surrogate marker of IR was recently suggested to be the triglyceride-glucose (TyG) index, which is calculated using fasting triglyceride (TG) and fasting glucose measurements (7–9).

Several previous studies indicated that the TyG index is associated with CAC and CVD (10–14); however, the results were inconsistent. In addition, although CAC progression is a powerful predictor of mortality compared with baseline CACS and traditional cardiovascular risk factors (15), no previous study has investigated the relationship between TyG index and CAC progression in adults. Therefore, we

¹Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

²Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul, Korea

³Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Corresponding author: Jong Suk Park, pjs00@yuhs.ac

Received 13 September 2018 and accepted 17 May 2019

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc18-1920/-/DC1>.

© 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

examined the relation between baseline TyG index level and CAC progression in a population of Korean adults.

RESEARCH DESIGN AND METHODS

Study Population

In this retrospective longitudinal study, subjects comprised 9,581 Korean adults who, as part of a self-referred checkup program, underwent cardiac CT examination at the Gangnam Severance Hospital Health Promotion Center in Seoul, Korea, between July 2006 and April 2018. Initially, 1,329 individuals who had undergone at least two cardiac CT scans were enrolled. Patients with an elevated TG level (≥ 400 mg/dL) ($n = 38$), any malignancy ($n = 9$), acute inflammatory disease ($n = 4$), renal disease ($n = 4$), missing data ($n = 11$), or a history of previous cerebrovascular event, myocardial infarction, or angina ($n = 73$) were excluded. Patients taking medications to lower TGs (e.g., fenofibrate or omega-3) ($n = 15$) were also not included in the study. Finally, 1,175 subjects were analyzed (Fig. 1). This study was approved by the institutional review board of Yonsei University College of Medicine.

Anthropometric Measurement and Laboratory Assessment

Subjects wore light clothing without shoes during body weight measurements. BMI was determined by dividing body weight in kilograms by height in meters squared. Measurements of systolic blood pressure (SBP) and diastolic blood

pressure (DBP) were taken by trained nurses with an automatic blood pressure monitor (HEM-7080IC; Omron Healthcare, Lake Forest, IL).

All subjects were examined after fasting for 12 h. Blood chemistry (TG, total cholesterol [TC], HDL cholesterol [HDL-C], and fasting plasma glucose [FPG]) was assessed using a Hitachi 7600-120 automated chemistry analyzer (Hitachi, Tokyo, Japan). Calculation of LDL cholesterol (LDL-C) was done using the Friedewald equation. TyG index was calculated as $\ln(\text{fasting TGs [mg/dL]} \times \text{fasting glucose [mg/dL]}/2)$.

Data on lifestyle habits, personal medical information, and medication history were collected with a questionnaire. A subject was considered a current smoker if he or she smoked regularly in the past 6 months. A subject who consumed alcoholic drinks more than three times a week was considered a current drinker. Exercise with moderate intensity for more than a half hour at least three times a week was defined as a regular exerciser. A subject was considered to have diabetes on the basis of a previous history of diabetes, current use of antidiabetic medications, or ADA diagnostic guidelines. An SBP or a DBP $\geq 140/90$ mmHg and antihypertensive medication use were considered as criteria for hypertension.

CACS Measurement

A multidetector CT scanner (Philips Brilliance 64; Philips Medical Systems, Best,

the Netherlands) was used to measure CACS. A prospective ECG gating protocol with a step-and-shoot technique was used (16). All subjects were in the supine position and held their breath during the imaging process. One of three trained radiologists, all of whom were blinded to the laboratory and clinical information, performed the analysis of coronary CT images. The CACS was quantified automatically with dedicated software, and the severity was assessed using the Agatston score (Aquarius Workstation; TeraRecon, Foster City, CA). A CACS > 0 was defined as CAC. CAC progression was defined as either 1) incident CAC, indicating a baseline Agatston score of 0 but detectable CAC at follow-up examination in a population free from CAC at baseline (17) or 2) an increase of ≥ 2.5 units between baseline and the final square root of CACSs in subjects with detectable CAC at baseline (18). Change in square root-transformed CAC ($\Delta\sqrt{\text{transformed CAC}}$) was annualized with the interscan period (annualized $\Delta\sqrt{\text{transformed CAC}}$).

Statistical Analysis

Continuous variables are shown as mean \pm SD; χ^2 tests were done to compare categorical variables, expressed as percentages. ANOVA was used for between-group analyses. The association between CAC progression and the TyG index was assessed by logistic regression after adjustment for any potential confounders. In the multivariable model, the following covariates were chosen because of their clinical importance and statistical significance in the univariable analysis: age, sex, BMI, SBP, LDL-C, HDL-C, exercise, alcohol, smoking, presence of diabetes or hypertension, use of statins or aspirin, and baseline $\ln(\text{CACS} + 1)$. In addition, we further adjusted for change in BMI, SBP, LDL-C, HDL-C, and TyG index and change in whether taking drugs for diabetes and hypertension, statins, or aspirin. In separate models, we assessed the multivariable-adjusted relationship of TyG index with CAC incidence and CAC progression of subjects with detectable CAC at baseline (increase ≥ 2.5 units between baseline and final square root of CACSs). Statistical analyses were done using SPSS version 23.0 software (IBM Corporation, Chicago, IL), and $P < 0.05$ was considered statistically significant.




Figure 1—Study flow.

RESULTS

Baseline Characteristics

The mean age of the 1,175 subjects at baseline was 51 ± 7 years, and 71.1% of subjects were men ($n = 835$). The included subjects were stratified into three groups on the basis of TyG index level. The biochemical parameters and clinical characteristics of the study subjects are presented in Table 1. TC, LDL-C, FPG, and TG levels and BMI, DBP, and SBP were elevated, whereas HDL-C was decreased in subjects with a high TyG index. Likewise, the high TyG index group had more hypertension, diabetes, alcohol consumption, and current smoking. Baseline CACS values were also higher with a higher TyG index. These trends were still observed after follow-up (Supplementary Table 1).

Comparison of Variables in Relation to the Degree of CAC Progression

Subjects were stratified into three groups on the basis of the severity of CAC progression (any increase in CACS was considered as CAC progression): no progression, CAC progression of 0 to <100 , CAC progression of ≥ 100 (Table 2). Subjects who showed more CAC progression were of older age; more often men; more likely to have elevated baseline SBP, DBP, BMI, FPG, TG, hypertension, diabetes, exercise, and baseline CACS; and more likely to have a lower HDL-C. When TyG index level was compared according to CAC progression severity, TyG index level increased significantly as CAC severity increased from a CACS of 0 to ≥ 100 (Table 2).

CACS Change According to TyG Index Level

Table 1 presents the follow-up CACS according to TyG index. The average follow-up period was 4.2 ± 2.2 years, and there was no significant difference among the three groups. Follow-up CACS and incidence of CAC progression increased significantly with a rise in TyG index tertile.

Figure 2 shows that both the $\Delta\sqrt{\text{transformed}}$ CACSs (tertile 1 [T1] 0.92 ± 2.37 , T2 1.30 ± 2.87 , T3 2.26 ± 4.03 ; $P < 0.01$) and annualized $\Delta\sqrt{\text{transformed}}$ CACSs (T1 0.20 ± 0.67 , T2 0.36 ± 1.32 , T3 0.48 ± 0.84 ; $P < 0.01$) increased across tertiles of TyG index at baseline. The group with a higher TyG index had greater $\Delta\sqrt{\text{transformed}}$ CACSs and annualized $\Delta\sqrt{\text{transformed}}$ CACSs.

Association Between CAC Progression and TyG Index

Univariable logistic regression analysis indicated that age, male sex, BMI, SBP, DBP, HDL-C, baseline CACS, and presence of hypertension or diabetes were statistically associated with CAC progression. In addition, increasing TyG index tertile was significantly correlated with risk of CAC progression (Supplementary Table 2). Taking T1 as the reference, multivariable logistic regression analysis revealed that the TyG index levels for T2 and T3 increased the odds ratios for CAC progression (Table 3). This relationship remained statistically significant after adjustment for sex, age, and other risk factors. In addition, after adjusting for confounding variables, including change in BMI, SBP, LDL-C, HDL-C, and TyG index and change in whether taking drugs for diabetes and hypertension, statins, or aspirin, these relationships were statistically significant (Supplementary Table 3).

Furthermore, we performed the multivariable logistic regression analysis separately for incident CAC and CAC progression of subjects with detectable CAC at baseline. In both groups, TyG index was an independent predictive marker (Supplementary Table 4).

CONCLUSIONS

In the current study, we noticed a significant association between CAC progression and TyG index in Korean adults. Even after adjusting for cardiovascular risk factors, there was an independent association of TyG index with CAC

Table 1—Characteristics of participants according to TyG index tertiles

	T1	T2	T3	P value
<i>n</i>	392	391	392	
Age (years)	51.9 ± 8.1	52.0 ± 7.8	51.5 ± 7.2	0.67
Sex (<i>n</i> male/ <i>n</i> female)	192/200	293/98	350/42	
SBP (mmHg)	119.2 ± 15.6	124.9 ± 15.9	127.1 ± 15.0	<0.01
DBP (mmHg)	74.0 ± 10.0	78.5 ± 9.7	80.4 ± 8.7	<0.01
BMI (kg/m ²)	22.9 ± 2.7	24.3 ± 2.8	25.3 ± 2.8	<0.01
FPG (mg/dL)	89.4 ± 10.6	98.7 ± 13.1	105.9 ± 21.2	<0.01
TC (mg/dL)	188.4 ± 31.2	196.3 ± 36.6	204.9 ± 36.8	<0.01
TG (mg/dL)	64.9 ± 14.0	106.2 ± 18.2	194.2 ± 56.8	<0.01
HDL-C (mg/dL)	58.0 ± 12.3	50.2 ± 11.7	44.0 ± 9.5	<0.01
LDL-C (mg/dL)	116.7 ± 30.0	126.0 ± 31.9	130.0 ± 34.1	<0.01
TyG index	7.94 ± 0.26	8.54 ± 0.14	9.18 ± 0.29	<0.01
Hypertension	68 (17.3)	117 (29.9)	132 (33.8)	<0.01
Diabetes	8 (2.0)	28 (7.2)	62 (15.9)	<0.01
Statin use	8 (2.0)	17 (4.3)	19 (4.9)	0.09
Alcohol	46 (11.7)	63 (16.1)	79 (20.2)	<0.01
Smoking	20 (5.1)	46 (11.8)	67 (17.1)	<0.01
Exercise	62 (15.8)	87 (22.3)	62 (15.8)	0.03
Baseline CACS	14.0 ± 56.0	25.7 ± 80.1	28.8 ± 94.0	0.02
Categorical CACS				<0.01
0	305 (77.8)	271 (69.3)	267 (68.1)	
0 to ≤ 10	25 (6.4)	30 (7.7)	26 (6.6)	
>10	62 (15.8)	90 (23.0)	99 (25.3)	
Follow-up CACS	28.0 ± 89.7	49.9 ± 138.9	74.9 ± 208.8	<0.01
Categorical CACS				<0.01
0	280 (71.4)	237 (60.6)	202 (51.5)	
0 to ≤ 10	17 (4.3)	26 (6.6)	29 (7.4)	
>10	95 (24.2)	128 (32.7)	161 (41.1)	
Baseline ln(CACS + 1)	0.72 ± 1.50	1.10 ± 1.84	1.15 ± 1.85	<0.01
Follow-up ln(CACS + 1)	1.07 ± 1.86	1.55 ± 2.14	1.96 ± 2.25	<0.01
Observation time (years)	4.2 ± 2.2	4.0 ± 2.1	4.4 ± 2.3	0.06
CAC progression	69 (17.6)	100 (25.6)	143 (36.5)	<0.01

Data are mean \pm SD or *n* (%). Alcohol, moderate drinking; CAC progression, incident CAC or increase ≥ 2.5 units between baseline and final square root of CACSs; exercise, regular exercise of moderate intensity; smoking, current smoker.

Table 2—Baseline characteristics of subjects by change in CACS at follow-up

	No change	0 < CACS change <100	CACS change ≥100	P value
<i>n</i>	755	331	89	
Age (years)	50.0 ± 7.0	54.4 ± 8.0	56.8 ± 8.0	<0.01
Sex (<i>n</i> male/ <i>n</i> female)	479/276	274/57	82/7	
SBP (mmHg)	121.8 ± 15.7	126.9 ± 15.2	128.4 ± 17.0	<0.01
DBP (mmHg)	76.5 ± 9.8	79.3 ± 9.6	80.6 ± 9.8	<0.01
BMI (kg/m ²)	23.8 ± 3.0	24.7 ± 2.6	25.3 ± 2.8	<0.01
FPG (mg/dL)	95.6 ± 15.6	101.5 ± 17.6	105.0 ± 22.0	<0.01
TC (mg/dL)	195.5 ± 35.1	200.0 ± 35.9	192.8 ± 38.3	0.09
TG (mg/dL)	116.7 ± 62.2	130.1 ± 67.9	133.7 ± 67.1	<0.01
HDL-C (mg/dL)	51.7 ± 13.2	49.4 ± 11.6	48.1 ± 10.1	<0.01
LDL-C (mg/dL)	122.7 ± 31.7	128.9 ± 33.2	119.9 ± 34.5	<0.01
TyG index	8.49 ± 0.57	8.66 ± 0.54	8.72 ± 0.51	<0.01
Hypertension	164 (21.7)	112 (33.8)	41 (46.6)	<0.01
Diabetes	39 (5.2)	43 (13.0)	13 (18.2)	<0.01
Statin use	21 (2.8)	19 (5.7)	4 (4.5)	0.06
Alcohol	121 (16.0)	47 (14.2)	20 (22.7)	0.15
Smoking	86 (11.4)	34 (10.3)	13 (14.8)	0.49
Exercise	119 (15.8)	71 (21.5)	21 (23.9)	0.03
Baseline CACS	3.67 ± 22.29	34.31 ± 87.30	142.82 ± 176.54	<0.01
Baseline ln(CACS + 1)	0.24 ± 0.90	1.86 ± 1.89	4.07 ± 1.72	<0.01

Data are mean ± SD or *n* (%). Alcohol, moderate drinking; exercise, regular exercise of moderate intensity; smoking, current smoker.

progression. To our knowledge, this study is the first to reveal a longitudinal association of TyG index and CAC progression. These results also demonstrate an association between increased TyG index level and traditional CVD risk factors, which is consistent with previous studies (10–12,19–21).

CAC prevalence is considered a surrogate marker for predicting CVD risk; we reported a significant association of the

TyG index with CAC prevalence in a previous cross-sectional study (10). Because of this, a causal relationship between TyG index and CAC could not be demonstrated. In the current study, the baseline and follow-up CACSs increased according to TyG index level, and subjects who experienced CAC progression during follow-up had a significantly higher baseline TyG index. Besides, we also showed that the TyG index was independently associated

with CAC progression, regardless of conventional risk factors. Recent cross-sectional reports have demonstrated a positive correlation between TyG index and CAC (10,11,14); however, earlier studies did not address the relationship between CAC progression and TyG index.

Although the mechanism underlying the association is still unclear, the TyG index is a surrogate marker of IR, which may be important. Many studies have indicated the importance of IR not only in atherogenesis but also in advanced plaque progression by promoting apoptosis of macrophages, endothelial cells, and vascular smooth muscle cells (22–26). Furthermore, IR has been shown to be independently associated with CAC progression. In a population-based study performed by Yamazoe et al. (27), IR, assessed as HOMA-IR, was an independent predictor of CAC progression in Japanese men without diabetes. Sung et al. (28) also showed that HOMA-IR was independently associated with an increase in CAC. In contrast, such an independent association between IR and CAC progression was not observed in some studies. Blaha et al. (29) reported an association between HOMA-IR and CAC progression and incidence, but it was not predictive after adjustment for the components of metabolic syndrome and other established risk factors. Lee et al. (30) observed no association of HOMA-IR with CAC progression in a community-based population without clinical coronary artery disease. These discrepancies call for further large-scale prospective studies to clarify this relationship and the involved mechanisms.

Our study has several limitations. The results may not be generalizable because most subjects were relatively young and male. Only subjects who repeated coronary CT scans were enrolled in this study, so there may be a selection bias. Subjects who had higher CVD risk were more likely to be enrolled in the study. The follow-up period was short and varied, even though baseline characteristics differed among CAC progression groups. Although we statistically adjusted for confounding factors in our multivariable regression, the adjustment may not have entirely removed confounding factors. The potential effects of medications taken for hypertension and diabetes on CAC progression could not be eliminated in this study. Because




Figure 2—Change of CAC according to TyG index tertiles.

Table 3—CAC progression according to TyG index tertiles

TyG index	OR (95% CI)			P value for trend
	T1	T2	T3	
Model 1	1.00	1.61 (1.14–2.27)	2.69 (1.93–3.75)	<0.01
Model 2	1.00	1.36 (1.94–1.96)	2.13 (1.49–3.06)	<0.01
Model 3	1.00	1.15 (0.78–1.71)	1.82 (1.20–2.77)	<0.01

Model 1: unadjusted. Model 2: adjusted for age and sex. Model 3: model 2 + BMI, SBP, LDL-C, HDL-C, exercise, alcohol, smoking, presence of diabetes and hypertension, use of statins and aspirin, and baseline ln(CACS + 1). OR, odds ratio.

this was an observational study, some of the responses to the questionnaire on medication history may have been inaccurate, and there was a lack of information on dose and class of antihypertensive and antidiabetic drugs. Therefore, the effects of hypertension and diabetes medications were not considered, and changes in whether taking drugs for diabetes and hypertension, statins, or aspirin were considered instead in the analysis. Finally, HOMA-IR was not analyzed and compared with TyG index because insulin levels were not measured in the general health checkup. Despite these limitations, this study has significant implications that are clinically relevant because it is the first to investigate the association between TyG index and CAC progression.

In this study, an independent association of elevated TyG index level with CAC progression was seen regardless of other conventional CVD risk factors. The TyG index might be an important predictor of CAC progression, reflecting cardiovascular risk.

Acknowledgments. The authors thank Gangnam Severance Hospital Health Promotion Center for its role in the collection, maintenance, and support of the database. The authors also thank the Biostatistics Collaboration Unit, Department of Research Affairs, Yonsei University College of Medicine, for help with analyzing the database. **Duality of Interest.** No potential conflicts of interest relevant to this article were reported. **Author Contributions.** K.P. researched data and wrote the manuscript. C.W.A., S.K., J.S.N., and J.H.K. contributed to interpreting the findings and editing the manuscript. S.B.L. and B.K.L. contributed to collecting data. J.S.P. designed the study and analyzed and interpreted the study data. J.S.P. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score

combined with Framingham score for risk prediction in asymptomatic individuals. *JAMA* 2004; 291:210–215

2. Youssef G, Budoff MJ. Coronary artery calcium scoring, what is answered and what questions remain. *Cardiovasc Diagn Ther* 2012;2:94–105

3. Lee KY, Hwang BH, Kim TH, et al. Computed tomography angiography images of coronary artery stenosis provide a better prediction of risk than traditional risk factors in asymptomatic individuals with type 2 diabetes: a long-term study of clinical outcomes. *Diabetes Care* 2017; 40:1241–1248

4. Agarwal S, Cox AJ, Herrington DM, et al. Coronary calcium score predicts cardiovascular mortality in diabetes: Diabetes Heart Study. *Diabetes Care* 2013;36:972–977

5. Ginsberg HN. Insulin resistance and cardiovascular disease. *J Clin Invest* 2000;106:453–458

6. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. *Diabetes Care* 2002;25:1177–1184

7. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. *Metab Syndr Relat Disord* 2008;6:299–304

8. Vasques AC, Novas FS, de Oliveira MdaS, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. *Diabetes Res Clin Pract* 2011; 93:e98–e100

9. Guerrero-Romero F, Villalobos-Molina R, Jiménez-Flores JR, et al. Fasting triglycerides and glucose index as a diagnostic test for insulin resistance in young adults. *Arch Med Res* 2016; 47:382–387

10. Kim MK, Ahn CW, Kang S, Nam JS, Kim KR, Park JS. Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults. *Cardiovasc Diabetol* 2017;16:108

11. Lee EY, Yang HK, Lee J, et al. Triglyceride glucose index, a marker of insulin resistance, is associated with coronary artery stenosis in asymptomatic subjects with type 2 diabetes. *Lipids Health Dis* 2016;15:155

12. Sánchez-Íñigo L, Navarro-González D, Fernández-Montero A, Pastrana-Delgado J, Martínez JA. The TyG index may predict the development of cardiovascular events. *Eur J Clin Invest* 2016;46:189–197

13. Vega GL, Barlow CE, Grundy SM, Leonard D, DeFina LF. Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men. *J Invest Med* 2014;62:345–349

14. Won KB, Kim YS, Lee BK, et al. The relationship of insulin resistance estimated by triglyceride glucose index and coronary plaque characteristics. *Medicine (Baltimore)* 2018;97:e10726

15. Budoff MJ, Hokanson JE, Nasir K, et al. Progression of coronary artery calcium predicts all-cause mortality. *JACC Cardiovasc Imaging* 2010;3:1229–1236

16. Jung DH, Lee HR, Lee YJ, Kim JK, Park BJ, Shim JY. The association between coronary artery calcification and mean platelet volume in the general population. *Platelets* 2011;22:567–571

17. DeFilippis AP, Blaha MJ, Ndumele CE, et al. The association of Framingham and Reynolds risk scores with incidence and progression of coronary artery calcification in MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol* 2011;58:2076–2083

18. Hokanson JE, MacKenzie T, Kinney G, et al. Evaluating changes in coronary artery calcium: an analytic method that accounts for interscan variability. *AJR Am J Roentgenol* 2004;182:1327–1332

19. Zheng R, Mao Y. Triglyceride and glucose (TyG) index as a predictor of incident hypertension: a 9-year longitudinal population-based study. *Lipids Health Dis* 2017;16:175

20. Jian S, Su-Mei N, Xue C, Jie Z, Xue-Sen W. Association and interaction between triglyceride-glucose index and obesity on risk of hypertension in middle-aged and elderly adults. *Clin Exp Hypertens* 2017;39:732–739

21. Lee DY, Lee ES, Kim JH, et al. Predictive value of triglyceride glucose index for the risk of incident diabetes: a 4-year retrospective longitudinal study. *PLoS One* 2016;11:e0163465

22. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. *Cell Metab* 2011;14:575–585

23. Pansuria M, Xi H, Li L, Yang XF, Wang H. Insulin resistance, metabolic stress, and atherosclerosis. *Front Biosci (Schol Ed)* 2012;4:916–931

24. Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. *Diabetes Care* 2012;35:2359–2364

25. Reardon CA, Lingaraju A, Schoenfeldt KQ, et al. Obesity and insulin resistance promote atherosclerosis through an IFN γ -regulated macrophage protein network. *Cell Rep* 2018;23:3021–3030

26. Linton MF, Fazio S. Macrophages, inflammation, and atherosclerosis. *Int J Obes Relat Metab Disord* 2003;27(Suppl. 3):S35–S40

27. Yamazoe M, Hisamatsu T, Miura K, et al.; SESSA Research Group. Relationship of insulin resistance to prevalence and progression of coronary artery calcification beyond metabolic syndrome components: Shiga Epidemiological Study of Subclinical Atherosclerosis. *Arterioscler Thromb Vasc Biol* 2016;36:1703–1708

28. Sung KC, Ryu S, Lee JY, et al. Fatty liver, insulin resistance, and obesity: relationships with increase in coronary artery calcium over time. *Clin Cardiol* 2016;39:321–328

29. Blaha MJ, DeFilippis AP, Rivera JJ, et al. The relationship between insulin resistance and incidence and progression of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). *Diabetes Care* 2011;34:749–751

30. Lee KK, Fortmann SP, Fair JM, et al. Insulin resistance independently predicts the progression of coronary artery calcification. *Am Heart J* 2009; 157:939–945